Advertisement
News
Advertisement

Avedro lands second FDA orphan drug status

Wed, 12/07/2011 - 8:38am
Mass High Tech: The Journal of New England Technology

The U.S. Food and Drug Administration has granted a second orphan drug designation to Waltham ophthalmologic device and pharmaceutical developer Avedro Inc. for a treatment of corneal ectasia. The designation relates to VibeX, its riboflavin solution intended for use with UVA irradiation, the KXL system for Corneal Cross-linking, which the company said on its website helps strengthen the cornea following refractive surgery.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading